The SNIFFPHONE Consortium

Ten international partners cooperate in this project to make disease detection via Smart Phone a reality.

Cellix Limited, Ireland,
Leader: Mr. Dmitry Kashanin
www.cellixltd.com

JLM Innovation GmbH, Germany
Leader: Dr. Jan Mitrovics
www.jlm-innovation.de

microfluidic ChipShop Gmbh, Germany
Leader: Dr. Holger Becker
www.microfluidic-chipshop.com

NanoVation, Israel
Leader: Dr. Gregory Shuster
www.nanovation-gs.com

Siemens AG, Corporate Technology, Germany
Leader: Dr. Roland Pohle
www.siemens.com/ingenuityforlife

Siemens Healthineers, Germany
Leader: Dr. Maria Sramek
www.healthcare.siemens.de

Technion – Israel Institute of Technology, Israel
Leader: Prof. Hossam Haick
www.technion.ac.il

University of Innsbruck, Austria
Leader: Dr. Pawel Mochalski
www.uibk.ac.at

University of Latvia, Latvia
Leader: Prof. Marcis Leja
www.lu.lv

VTT Technical Research Centre of Finland, Finland
Leader: Mr. Raimo Launonen
www.vttresearch.com

www.sniffphone.eu

SNIFFPHONE

SNIFFPHONE Contact Details

Project Coordinator
Prof. Hossam Haick
Head of the Laboratory for Nanomaterial-Based Devices (LNBD) and Volatile Biomarkers
Technion - Israel Institute of Technology
Haifa 3200003, Israel
Tel: +972-4-8293087 | Fax: +972-77-8871880
Email: hhossam@technion.ac.il
http://lnbd.technion.ac.il

Prototype and System Integration:
JLM Innovation GmbH
Dr. Jan Mitrovics
Vor dem Kreuzberg 17, 72072 Tübingen
Tel: +49-7071-5667730
Email: jan.mitrovics@jlm-innovation.de
www.jlm-innovation.de

www.sniffphone.eu

Smart Systems Integrated

Got it

Funded by the European Union's Horizon 2020 Programme for research, technological development and demonstration under grant agreement No 644031.

SNIFFPHONE

SNIFFPHONE

Smart Phone for Disease Detection from Exhaled Breath

Smart Phone for Disease Detection from Exhaled Breath

Most Innovative project ECS European Commission 2018

All about the SNIFFPHONE

Screening for cancer made easy:

SniffPhone is a handheld device for breath analysis used for early diagnosis of cancer.

The advantages over traditional screening methods are unparalleled:

- **comfortable and painless for patients**
- **Easy to use by care providers**
- **Cost efficient in acquisition and maintenance**
- **Provides real time results**

How does it work?

The user exhales onto the SniffPhone.

The device then takes a sample of the exhaled breath, measuring the contained Volatile Organic Compounds (VOCs) using highly sensitive nanotechnology-based chemical sensors.

The measurements are sent via Bluetooth using a smartphone to a dedicated cloud platform, where they are analyzed by smart algorithms.

With the instant results care providers can tell the patients whether they should come in for further testing or treatment.

SniffPhone – High Tech that is Low Maintenance for patients and doctors!



Baseline measurement | *Breath sample measurement* | *Background data* | *Diagnosis Result*

SNIFFPHONE

SNIFFPHONE evolves

SniffPhone has completed a first round of clinical trials with very promising results. Extensive usability tests in real life settings and feedback collected from researchers and end users helped to evolve SniffPhone to a truly remarkable technology platform.

Sleek, smart, and easy to use!

As a next step, SniffPhone is looking for investors to bring this exceptional research project to the market through a spin-off company.

The potential of this technology platform could revolutionize cancer screening for patients all over the world.

2018 Innovation Award

SniffPhone has been awarded the 2018 Innovation Award by the European Commission for Most Innovative Project. The Award was granted on the 21st of November in Lisbon, at the European Forum for Electronic Components and System (EFECS).

ECS European Commission

SNIFFPHONE

Core Advantages

- Smart systems integrated with cloud services
- Autonomous battery operation
- Easy-to-use

Advanced Technology

- Sensors based on nanomaterials
- Automated measurement process

Application Areas

- Widespread health screening
- Early diagnosis
- Personalized medicine